⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12540439 | 0.89 | RXFP1 (0.34) | — | |
| SCHEMBL1983718 | 0.85 | — | — | |
| SCHEMBL1979806 | 0.84 | — | — | |
| SCHEMBL15702207 | 0.80 | — | — | |
| SCHEMBL12540091 | 0.79 | — | — | |
| SCHEMBL1991321 | 0.75 | — | — | |
| SCHEMBL12540045 | 0.74 | — | — | |
| SCHEMBL2028356 | 0.73 | MAPK13 (0.33) | — | |
| SCHEMBL2008973 | 0.70 | CYP1A2 (0.31) | — | |
| Dimethylamine SCHEMBL12545167 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509964-B1 | Heterocyclic sulfonamide derivatives | NOVARTIS AG (CH) | 2014-04-30 | — | — | EP | disclosed |
| US-8614239-B2 | Heterocyclic sulfonamide derivatives | NOVARTIS AG (CH) | 2013-12-24 | — | — | US | disclosed |
| EP-2509964-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES | Novartis AG (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-20120245209-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | disclosed |
| US-20120245209-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | disclosed |
| US-20120245209-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | disclosed |
| WO-2011070030-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-06-16 | — | — | WO | disclosed |